Filing Details
- Accession Number:
- 0001439222-24-000050
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-05 16:15:23
- Reporting Period:
- 2024-03-01
- Accepted Time:
- 2024-03-05 16:15:23
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1439222 | Agios Pharmaceuticals Inc. | AGIO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1874199 | Jr. James Theodore Washburn | 88 Sidney Street Cambridge MA 02139 | Principal Accounting Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-03-01 | 777 | $0.00 | 3,663 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-03-05 | 295 | $32.57 | 3,368 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-03-01 | 2,350 | $0.00 | 5,718 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-03-05 | 919 | $32.57 | 4,799 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted stock units | Acquisiton | 2024-03-01 | 7,350 | $0.00 | 7,350 | $0.00 |
| Common Stock | Restricted stock units | Disposition | 2024-03-01 | 777 | $0.00 | 777 | $0.00 |
| Common Stock | Restricted stock units | Disposition | 2024-03-01 | 2,350 | $0.00 | 2,350 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 7,350 | No | 4 | A | Direct | ||
| 777 | No | 4 | M | Direct | ||
| 4,700 | No | 4 | M | Direct |
Footnotes
- Includes 752 shares purchased through the Company's employee stock purchase plan.
- Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2022.
- Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023.
- Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments.
- The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.
- The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.
Billionaire Hedge Funds
